课题基金 / 基金详情

REGULATION OF ZINC PROTEINS AND CELLULAR ZINC HOMEOSTASIS

REGULATION OF ZINC PROTEINS AND CELLULAR ZINC HOMEOSTASIS
锌蛋白和细胞锌稳态的调节
批准号:
07457541
负责人:
OGURI Kazuta
金额:
$0.96万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
1995
资助国家:
日本
项目状态:
已结题
起止时间:
1995 至 1996

项目摘要

项目成果

OGURI Kazuta的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Toxic manifestation of coplanar PCB is thought to be mediated by aromatic hydrocarbon (Ah)-receptor. However, the suppression of protein expression by coplanar PCBs is scarcely clarified. We report here the suppression of cytosolic proteins by a coplanar PCB-treatment and propose new aspects of the toxicity. Male Wistar rats were treated with PenCB (single 25 mg/kg, i. p.). Free- and pair-fed control groups were treated with vehicle. At the day 5, the liver cytosol was prepared. The cytosolic proteins were compared among three groups by SDS-PAGE and two-dimensional RAGE (2D-PAGE). Expression level of cytosolic 40-kDa and 27-kDa proteins in rat liver were markedly suppressed by PenCB-treatment. The 40-kDa proteins were identified as aldolase B (Ald B) and alcohol dehydrogenase (ADH) class I by amino acid sequencing of the internal peptides. The 27-kDa protein was also identified as carbonic anhydrase III (CA II). The liver cytosolic Ald and ADH activities were significantly reduced to about 50% and 60% of both control groups by PenCB-treatment. Immunoblotting after sD-PAGE demonstrated that Ald B was markedly suppressed by PenCB-treatment, while change in Ald A was slight. The reduction of ADH by PenCB-treatment was also verified by immunoblotting. The significant suppression of CA III by PenCB-treatment in rat liver was demonstrated by immunoblotting using CA III-selective antibody. Ald plays an important role in glycolytic and gluconeogenetic pathways. In addition, ADH catalyzes biotransformation of triose phosphate to glycerol-3-phosphate. Sippression of Ald B and ADH may be a key biochemical lesion for disordered intermediary metabolism occurring by PenCB-treatment and should be taken into an account as a cause of the wasting syndrom which is a severe toxic effect of toxic coplanar PCBs. CA III possesses tyrosine phosphatase activity, therefore, its suppression could account for the effects on signal transduction by toxic coplanar PCBs.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
Yuji Ishii et al.: "Significant suppression of rat liver aldolase B by a toxic coplanar polychlorinated biphenyl,3,3',4,4',5-pentachlorobiphenyl" Toxicology. 116. 193-199 (1997)
Yuji Ishii 等人:“有毒的共面多氯联苯,3,3,4,4,5-五氯联苯对大鼠肝脏醛缩酶 B 的显着抑制”毒理学。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Yuji Ishii et al.: "Significant suppression of rat liver aldolase B by a toxic coplanar polychlorinated biphenyl,3,3′,4,4′,5-pentachlorobiohenyl" Toxicology. 116. 193-199 (1997)
Yuji Ishii 等人:“有毒的共面多氯联苯,3,3,4,4,5-五氯二苯基对大鼠肝脏醛缩酶 B 的显着抑制”毒理学。 116. 193-199 (1997)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Ishii, Y., Kato, H., Hatsumura, M., Ishida, T.Ariyoshi, N., Oguri, K.: "Significant suppression of rat liver aldolase B by a toxic coplanar polychlorinated biphenyl, 3,3', 4,4', 5-pentachlorobiphenyl" Toxicology. 116. 193-199 (1997)
Ishii, Y.、Kato, H.、Hatsumura, M.、Ishida, T.Ariyoshi, N.、Oguri, K.:“有毒共面多氯联苯对大鼠肝脏醛缩酶 B 的显着抑制,3,3, 4
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Studies on Narcotic UDP-Glucuronosyltransferases for effective and safty use in clinical application
  • 批准号:
    08557088
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
  • 资助金额:
    $7.74万
  • 财政年份:
    1996
  • 负责人:
    OGURI Kazuta
  • 依托单位:
Preparation of a High Performance Affinity Gel for Purification of UDP-Glucuronyltransferase
  • 批准号:
    01571213
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)
  • 资助金额:
    $1.34万
  • 财政年份:
    1989
  • 负责人:
    OGURI Kazuta
  • 依托单位:
国内基金
海外基金
靶向糖感知信号通路:TRPV5-Aldolase-AMPK调控前列腺癌细胞增殖与转移的机制与临床意义
  • 批准号:
    82072820
  • 项目类别:
    面上项目
  • 资助金额:
    55.0万元
  • 批准年份:
    2020
  • 负责人:
    温星桥
  • 依托单位:
靶向糖感知信号通路:TRPV5-Aldolase-AMPK调控前列腺癌细胞增殖与转移的机制与临床意义
  • 批准号:
    --
  • 项目类别:
    --
  • 资助金额:
    55万元
  • 批准年份:
    2020
  • 负责人:
    温星桥
  • 依托单位: